Hosseini Manji

I think there's no doubt it's opened the door. I would say both, you know, sort of this different type of treatment. And then what Spravato has also been able to do is, you know, sort of normalize to some extent the in-clinic administration. So I think that's one of the things that until Spravato came along, that simply wasn't the case. So I think it certainly has opened the door.

I think there's no doubt it's opened the door. I would say both, you know, sort of this different type of treatment. And then what Spravato has also been able to do is, you know, sort of normalize to some extent the in-clinic administration. So I think that's one of the things that until Spravato came along, that simply wasn't the case. So I think it certainly has opened the door.

I would say probably it'll depend on the indication. So I would say for treatment-resistant depression, it may be slightly more of a longer-term treatment because it just suggests that they've got bad illness. If they're not on treatment, the illness might come back.

I would say probably it'll depend on the indication. So I would say for treatment-resistant depression, it may be slightly more of a longer-term treatment because it just suggests that they've got bad illness. If they're not on treatment, the illness might come back.

I would say probably it'll depend on the indication. So I would say for treatment-resistant depression, it may be slightly more of a longer-term treatment because it just suggests that they've got bad illness. If they're not on treatment, the illness might come back.